2017
DOI: 10.1016/j.etp.2017.02.007
|View full text |Cite
|
Sign up to set email alerts
|

Sulfated glycosaminoglycans in bladder tissue and urine of rats after acute exposure to paraoxon and cyclophosphamide

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(8 citation statements)
references
References 33 publications
0
8
0
Order By: Relevance
“…It is presumed that the location of the parasite in the deeper mucosal layers may be to avoid direct contact with the urine at certain stages of their development. This results in recurrent urinary tract infections, interstitial cystitis, urolithiasis, and neoplastic changes (1,3,10,11,13,20,25).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…It is presumed that the location of the parasite in the deeper mucosal layers may be to avoid direct contact with the urine at certain stages of their development. This results in recurrent urinary tract infections, interstitial cystitis, urolithiasis, and neoplastic changes (1,3,10,11,13,20,25).…”
Section: Discussionmentioning
confidence: 99%
“…The urothelium surface is normally resilient to the biochemical components of the urine, microorganisms, and toxins. The local protection of the mucosal cells includes the tight junctions of umbrella cells (physical barrier) (5,9), glycosaminoglycans (9,11), cytokeratin (12), uroplakins (Upk1a, Upk1b, Upk2, Upk3a and Upk3b), and numerous membrane receptors (9,13).…”
Section: Introductionmentioning
confidence: 99%
“…We utilized two different animal models with normal and cystitis‐induced bladders to examine the effect of the anesthetic drug, lidocaine, released from the IUCs prepared in this study. The animal model with a cystitis‐induced bladder was prepared by intraperitoneal injection of 75 mg/kg CYP 3 days prior to IUC insertion 27 . As shown in Figure 2, we employed eight different groups ( n = 5 per group): NB: no treatment; normal bladder without treatment. NB: IUC; normal bladder implanted with the intact IUC. NB: PLGA_IUC; normal bladder implanted with the PLGA_IUC. NB: L_PLGA_IUC; normal bladder implanted with the L_PLGA_IUC. CYP: no treatment; cystitis‐induced bladder without treatment. CYP: IUC; Cystitis‐induced bladder implanted with the intact IUC. CYP: PLGA_IUC; cystitis‐induced bladder implanted with the PLGA_IUC. CYP: L_PLGA_IUC; cystitis‐induced bladder implanted with the L_PLGA_IUC. …”
Section: Methodsmentioning
confidence: 99%
“…We utilized two different animal models with normal and cystitis-induced bladders to examine the effect of the anesthetic drug, lidocaine, released from the IUCs prepared in this study. The animal model with a cystitis-induced bladder was prepared by intraperitoneal injection of 75 mg/kg CYP three days prior to IUC insertion (Sobolev, Jenkins, & Goncharov, 2017)…”
Section: Animalsmentioning
confidence: 99%
“…One of the most serious and difficult to treat side effects of CP administration is HC, which is characterized by diffuse inflammation and hemorrhage of the bladder mucosa [5]. Different treatments have been tried, such as oral or intravesical pentosane polysulfate [6], cystoProtek treatment [7], and cyclosporine therapy [8], all of which had several side effects. However, researchers still need to discover natural agents that could ameliorate CP-induced oxidative injury of the urinary bladder [9].…”
Section: Introductionmentioning
confidence: 99%